| Recruitment status | Preinitiation |
| Unique ID issued by UMIN | UMIN000022689 |
| Receipt No. | R000026154 |
| Official scientific title of the study | Examination of the lymphedema improvement with the surgical combination therapy for secondary limbs lymphedema |
| Date of disclosure of the study information | 2016/06/30 |
| Last modified on | 2016/06/10 (Ver. 1) |
| Basic information | ||
| Official scientific title of the study | Examination of the lymphedema improvement with the surgical combination therapy for secondary limbs lymphedema | |
| Title of the study (Brief title) | Examination of the lymphedema improvement with the surgical combination therapy | |
| Region |
|
|
| Condition | ||
| Condition | Lymphedema | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | We determine improvement with the surgical combination therapy for lymphedema |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Limbs circumference, ICG fluorescent lymphography, SF36 |
| Key secondary outcomes | |
| In outcomes field, the entry of just a few words such as "safety" or "efficiency" will not be accepted. Specify the name of outcome measures, including the time when you plan to measure. Usually, only one primary outcome is accepted. Write the other outcomes in "secondary outcomes" field. |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Active |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 3 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Vasculized lymph node transfer(VLNT)
|
|
| Interventions/Control_2 | Vasculized lymph node transfer, Lymphaticovenuler anastomosis(LVA) | |
| Interventions/Control_3 | Lymphaticovenuler anastomosis | |
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| In interventions field, include the details of interventions, such as duration, amount, and frequency. If the intervention includes prescription or use of medical devices, duration is required. |
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | The patients who there is secondary lymphedema, and expect surgical cure.
The person who is available for LVA conducts LVA by ICG lymphangiography. The person with the LVA treatment resistance receives LNT or VLNT+LVA. |
|||
| Key exclusion criteria | Those whom we considre inappropiate due to physical and/or mental problem | |||
| Target sample size | 50 | |||
| Research contact person | |
| Name of lead principal investigator | Yukiko Kuramoto |
| Organization | Cancer Institute Hospital |
| Division name | Department of Plastic and Reconstructive Surgery |
| Address | 3-8-31 Ariake, Koutou-ku, Tokyo, 135-8550 Japan |
| TEL | 03-3520-0111 |
| yukiko.kuramoto@jfcr.or.jp | |
| Public contact | |
| Name of contact person | Yukiko Kuramoto |
| Organization | Cancer Institute Hospital |
| Division name | Department of Plastic and Reconstructive Surgery |
| Address | 3-8-31 Ariake, Koutou-ku, Tokyo, 135-8550 Japan |
| TEL | 03-3520-0111 |
| Homepage URL | |
| yukiko.kuramoto@jfcr.or.jp | |
| Sponsor | |
| Institute | Cancer Institute Hospital |
| Institute | |
| Department | |
| Sponsor means an organization that is responsible for plan, deployment and report of the research including funding management. It doesn't mean funding agency". Therefore, all clinical trial should have the one. |
| Funding Source | |
| Organization | Cancer Institute Hospital |
| Organization | |
| Division | |
| Category of Funding Organization | Other |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Preinitiation | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000026154 |